A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE008 (KOR) · Dr. Kim
consented 2023-09-17
Adverse events
Grade 1 Hypothyroidism — outcome: RECOVERED/RESOLVED; onset 2023-11-02 (study day 36); relationship: Y
Grade 1 Colitis — outcome: RECOVERED/RESOLVED; onset 2023-11-16 (study day 50); relationship: not assessed
Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-12-08 (study day 72); relationship: not assessed
Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2024-02-08 (study day 134); relationship: not assessed
Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2024-03-16 (study day 171); relationship: not assessed
Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2024-04-11 (study day 197); relationship: not assessed
Grade 4 Decreased appetite — outcome: UNKNOWN; onset 2024-05-07 (study day 223); relationship: not assessed; serious criteria: life-threatening
Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2024-07-20 (study day 297); relationship: Y
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-09-28 (study day 367); relationship: not assessed
Data queries
No data queries.